Category: Latest News
-
Strategy introduces new data management tools at 2026 Gartner Summit
Strategy (NASDAQ:MSTR) unveiled two new solutions—Mosaic Sentinel and Cloud Cost Arbitrage—during the Gartner Data & Analytics Summit 2026, aiming to strengthen transparency, oversight, and governance in modern data environments. As businesses increasingly adopt AI-driven agents to handle data processing and analytics tasks, the company said the new tools are designed to give organizations greater visibility…
-
Autozi Internet shares surge 108% following $110M investment proposal
Autozi Internet Technology (NASDAQ:AZI) shares soared on Monday after the company announced a two-part financing update that quickly drew investor interest. The firm said its controlling shareholder had already completed an early capital injection of $7 million, fulfilling a previously announced commitment ahead of schedule. According to the company, the funds have been fully received…
-
Amazon Pharmacy launches Zepbound KwikPen with $299 monthly starting price
Amazon Pharmacy (NASDAQ:AMZN) said it has begun offering Eli Lilly’s Zepbound KwikPen, a multi-dose injectable medication for weight management, with cash-pay pricing starting at $299 per month for the 2.5 mg introductory dose, according to a company press release. The offering further expands Amazon’s growing presence in healthcare as the $2.29 trillion company continues broadening…
-
Xenon Pharmaceuticals shares jump 40% after strong Phase 3 seizure trial results
Shares of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) surged 40% on Monday after the company reported positive topline data from its Phase 3 X-TOLE2 trial evaluating azetukalner for focal onset seizures. The study achieved its primary endpoint in both tested dose groups. Patients receiving the 25 mg dose experienced a median reduction of 53.2% in monthly focal…
-
Dianthus Therapeutics shares jump 25% after encouraging clinical trial update
Dianthus Therapeutics Inc. (NASDAQ:DNTH) reported a fourth-quarter loss of $1.43 per share on Monday, while revenue totaled $280 thousand for the quarter ended December 31, 2025. Shares of the biotechnology company surged 25.05% in pre-market trading following the announcement. The company revealed it had reached an early GO decision in its Phase 3 CAPTIVATE trial…
-
uniQure shares jump 36% after news of FDA gene therapy chief’s departure
Shares of uniQure BV (NASDAQ:QURE) surged 36% on Monday after reports emerged that the head of the U.S. Food and Drug Administration’s vaccines and gene therapies division will step down, triggering several analyst upgrades across the biotechnology sector. Other companies in the space also rallied, with REGENXBIO (NASDAQ:RGNX) rising 13% and Biohaven (NYSE:BHVN) gaining 23%.…
-
Oracle refutes reports of issues at Abilene AI data center
Oracle Corporation (NYSE:ORCL) rejected recent media claims suggesting problems at its major AI data center in Abilene, Texas, saying the project remains on schedule and that it has secured the full 4.5 gigawatts of capacity pledged to OpenAI. Despite the clarification, Oracle shares were down 1.2% at $152.96 in pre-market trading, reflecting broader weakness across…
-
FuelCell Energy shares drop nearly 5% after Q1 loss despite strong revenue growth
FuelCell Energy, Inc. (NASDAQ:FCEL) reported fiscal first-quarter 2026 results on Monday, posting revenue of $30.5 million alongside an adjusted loss per share of $0.52 as the company continues shifting its strategy toward supplying power solutions for data centers. Shares of the company fell 4.74% in pre-market trading following the announcement. Revenue increased 61% year over…
-
Applied Optoelectronics stock rises on $200M transceiver order
Applied Optoelectronics Inc. (NASDAQ:AAOI) shares rose 2% Monday after the company announced it received its first volume order for 1.6T data center transceivers from a major hyperscale customer. The initial order totals more than $200 million and is expected to return the customer to its previous status as a 10%+ customer for Applied Optoelectronics, according to…
-
Boundless Bio posts smaller-than-expected Q4 loss
Boundless Bio (NASDAQ:BOLD) reported a fourth-quarter loss of $0.58 per share, beating analyst expectations for a loss of $1.16 per share, as the clinical-stage oncology company began enrolling patients in the first-in-human study of its BBI-940 therapy. The stock showed little movement in after-hours trading following the release of the results. Net loss for the…